GGTLC3 and hepatocellular carcinoma: The MELD score is used to assess the prognosis of patients with end‐stage liver disease, whereas cirrhosis s‐GGT has the greatest elevation and the median b‐GGT/s‐GGT ratio is lower than that of healthy controls, suggesting severe impairment of hepatic structural function, and the ratio is more diagnostically accurate than either s‐GGT or total GGT, even though total GGT is a sensitive biomarker of liver parenchymal rearrangement in patients with cirrhosis and hepatocellular carcinoma in both reference ranges, corresponding to a higher MELD score and poor prognosis [154].